A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Exclusion Criteria

• •Documented evidence of disease progression while on treatment (including SSAs) for locally advanced unresectable or metastatic disease
• •Known central nervous system metastases
• •Consecutive treatment with long-acting SSAs for more than 6 months before randomization
• •Carcinoid symptoms that are refractory to treatment (according to the Investigator's judgement) with conventional doses of octreotide LAR or lanreotide ATG and/or to treatment with daily doses of ≤600 µg of octreotide IR
• •Previous treatment with more than 1 cycle of targeted therapies such as mTOR inhibitors or vascular endothelial growth factor inhibitors, or more than 1 cycle of chemotherapy or interferon for GEP-NET
• •Treatment of GEP-NET with trans-arterial chemoembolization or trans-arterial embolization within 12 months before screening
• •Previously received radioligand therapy (PRRT) at any time